Incidence of Urinary Retention in Patients Undergoing Unilateral Total Knee Arthroplasty- Comparison Between Continuous Epidural Analgesia and Single Shot Femoral Nerve Block- a Randomized Controlled Study (UriKANE) (UriKANE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Karachi, Pakistan
- Aga Khan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASA Physical status I, II & III
- Male and Female Patients age between between 30 and 70 years
- Unilateral Total Knee Arthroplasty
Exclusion Criteria:
- Patient Refusal
- Allergy to local anesthetics, paracetamol or other study drugs
- History of opioid dependence
- Contraindications to spinal/epidural anesthesia and femoral nerve block (coagulation defects, infection at puncture site etc.)
- Inability to use patient-controlled analgesia (IV PCIA) (as assessed at the time of informed consent)
- History of urinary retention, neurogenic bladder, or any urologic problem
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group F
Femoral nerve Block Group
|
For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
|
|
Active Comparator: Group E
Epidural Group
|
Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region.
Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of urinary retention
Time Frame: 24 Hours
|
To compare the incidence of urinary retention in patients undergoing unilateral Total Knee Arthroplasty receiving continuous epidural analgesia vs. single shot Femoral Nerve Block.
|
24 Hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean post-operative nausea and vomiting scores
Time Frame: up to 48 hours
|
To compare the mean post-operative nausea and vomiting scores between the two groups at 0, 1, 12, 24 & 48 hours postoperatively.
|
up to 48 hours
|
|
Mean post-operative sedation scores
Time Frame: up to 48 hours
|
To compare the mean post-operative sedation scores between the two groups at 0, 1, 12, 24 & 48 hours postoperatively.
|
up to 48 hours
|
|
Mean post-operative pain scores
Time Frame: up to 48 hours
|
To compare the mean post-operative pain scores between the two groups at 0, 1, 12, 24 & 48 hours postoperatively.
|
up to 48 hours
|
|
Surgical outcomes - maximal knee flexion
Time Frame: up to 48 hours
|
To compare surgical outcomes like maximal knee flexion at 24 & 48 hours between the two groups
|
up to 48 hours
|
|
Surgical outcomes - duration of post-operative hospital stay
Time Frame: up to 48 hours
|
To compare surgical outcomes like duration of post-operative hospital stay between the two groups
|
up to 48 hours
|
|
Surgical outcomes - mobilization out of bed
Time Frame: up to 48 hours
|
To compare surgical outcomes like time taken to mobilize out of bed between the two groups
|
up to 48 hours
|
|
Surgical outcomes - food intake
Time Frame: up to 48 hours
|
To compare surgical outcomes like time of first food intake between the two groups
|
up to 48 hours
|
|
Patient satisfaction
Time Frame: 7 Days
|
To compare Patient satisfaction with the analgesic modality between the two groups
|
7 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ausaf A Khan, Aga Khan University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTU / UriKANE / 2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.